[{"id":"b1b80856-36d7-4b3b-b80b-159943ef72f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329065","created_at":"2021-01-18T20:58:01.125Z","updated_at":"2025-02-25T16:44:52.494Z","phase":"Phase 2","brief_title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","source_id_and_acronym":"NCT04329065","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-06"},{"id":"70b5ad20-490d-47a2-823e-d4e8dc4746f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01817452","created_at":"2021-01-17T17:34:12.030Z","updated_at":"2025-02-25T14:00:09.311Z","phase":"Phase 2","brief_title":"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol","source_id_and_acronym":"NCT01817452","lead_sponsor":"West German Study Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-11-13"},{"id":"c6eb5752-3b02-4b81-89d4-72c52d5a889a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04090398","created_at":"2021-01-18T20:01:06.898Z","updated_at":"2024-07-02T16:34:58.839Z","phase":"Phase 2","brief_title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","source_id_and_acronym":"NCT04090398","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-05"},{"id":"02e25d96-3ff3-4250-9821-ad530f91101e","acronym":"PEARLY","url":"https://clinicaltrials.gov/study/NCT02441933","created_at":"2021-01-18T11:41:58.115Z","updated_at":"2024-07-02T16:34:59.228Z","phase":"Phase 3","brief_title":"Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)","source_id_and_acronym":"NCT02441933 - PEARLY","lead_sponsor":"Yonsei University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 878","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"9a4a0bc7-29e9-4342-9fd2-fda5ba18ef80","acronym":"NRG-BR003","url":"https://clinicaltrials.gov/study/NCT02488967","created_at":"2021-01-18T11:59:46.930Z","updated_at":"2024-07-02T16:34:59.476Z","phase":"Phase 3","brief_title":"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02488967 - NRG-BR003","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 782","initiation":"Initiation: 07/26/2015","start_date":" 07/26/2015","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-06-03"},{"id":"afcedde0-6251-42ea-b45c-dec7e5e43b41","acronym":"DIMRISC-2","url":"https://clinicaltrials.gov/study/NCT04619186","created_at":"2021-01-19T20:34:08.198Z","updated_at":"2024-07-02T16:35:00.309Z","phase":"","brief_title":"Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of Breast Cancer","source_id_and_acronym":"NCT04619186 - DIMRISC-2","lead_sponsor":"Seoul National University Hospital","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"],"overall_status":"Suspended","enrollment":" Enrollment 1694","initiation":"Initiation: 12/30/2024","start_date":" 12/30/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-05-29"},{"id":"1da77410-a879-4bd0-ac76-26adfb53609a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05989828","created_at":"2023-08-14T14:10:18.266Z","updated_at":"2024-07-02T16:35:01.088Z","phase":"Phase 1","brief_title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","source_id_and_acronym":"NCT05989828","lead_sponsor":"University of Southern California","biomarkers":" HER-2 • PD-L1 • ER • PGR • CTAG1B","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-05-24"},{"id":"e5aa0f89-24de-40bf-8a67-186c3db1a88b","acronym":"ARC-2","url":"https://clinicaltrials.gov/study/NCT03719326","created_at":"2021-01-18T18:13:45.819Z","updated_at":"2024-07-02T16:35:01.152Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","source_id_and_acronym":"NCT03719326 - ARC-2","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2024-05-24"},{"id":"9a957162-f9ec-4d41-9b25-cad512d70cf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02295059","created_at":"2021-01-18T10:49:15.244Z","updated_at":"2024-07-02T16:35:01.286Z","phase":"","brief_title":"Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention","source_id_and_acronym":"NCT02295059","lead_sponsor":"City of Hope Medical Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER negative • PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-23"},{"id":"641e1e85-802d-456b-8ede-12ae69c97226","acronym":"NeoTENNIS","url":"https://clinicaltrials.gov/study/NCT04418154","created_at":"2021-01-18T21:17:40.275Z","updated_at":"2024-07-02T16:35:02.194Z","phase":"Phase 2","brief_title":"Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04418154 - NeoTENNIS","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-21"},{"id":"2d6f093a-de07-4209-b284-2545149189bc","acronym":"BRE-04","url":"https://clinicaltrials.gov/study/NCT04891068","created_at":"2021-05-18T12:02:05.434Z","updated_at":"2024-07-02T16:35:02.524Z","phase":"Phase 2","brief_title":"BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer","source_id_and_acronym":"NCT04891068 - BRE-04","lead_sponsor":"University of Illinois at Chicago","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/10/2022","start_date":" 01/10/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-20"},{"id":"c32f89f3-a298-4176-84bb-cec4e2a46e3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02398773","created_at":"2021-01-18T11:26:39.322Z","updated_at":"2024-07-02T16:35:02.895Z","phase":"Phase 2","brief_title":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","source_id_and_acronym":"NCT02398773","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER negative • PGR positive • PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR positive • PGR negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 05/04/2016","start_date":" 05/04/2016","primary_txt":" Primary completion: 04/04/2025","primary_completion_date":" 04/04/2025","study_txt":" Completion: 04/04/2025","study_completion_date":" 04/04/2025","last_update_posted":"2024-05-17"},{"id":"6218fa0c-7831-46e9-aa54-e8cf3a80ef2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05675579","created_at":"2023-01-09T15:59:22.277Z","updated_at":"2024-07-02T16:35:04.264Z","phase":"Phase 2","brief_title":"A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT05675579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • ER positive + PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • ER positive + PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-13"},{"id":"1694a214-0630-452e-9847-de4cf48eff13","acronym":"","url":"https://clinicaltrials.gov/study/NCT02926729","created_at":"2021-01-18T14:22:31.553Z","updated_at":"2024-07-02T16:35:04.817Z","phase":"","brief_title":"Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy","source_id_and_acronym":"NCT02926729","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • ER negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative • PGR positive • PGR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 07/17/2019","start_date":" 07/17/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-09"},{"id":"c5a7f9eb-55ee-4160-bb2f-095df5c5c5cc","acronym":"JEWEL-101","url":"https://clinicaltrials.gov/study/NCT04925284","created_at":"2023-05-03T19:04:55.692Z","updated_at":"2024-07-02T16:35:06.232Z","phase":"Phase 1","brief_title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","source_id_and_acronym":"NCT04925284 - JEWEL-101","lead_sponsor":"Exelixis","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Avastin (bevacizumab) • samatatug zovodotin (XB002)"],"overall_status":"Recruiting","enrollment":" Enrollment 573","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 10/07/2024","study_completion_date":" 10/07/2024","last_update_posted":"2024-05-03"},{"id":"c9892233-0e72-4b03-a1a6-ddcbeb8d59bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03289962","created_at":"2021-01-18T16:15:14.579Z","updated_at":"2024-07-02T16:35:07.331Z","phase":"Phase 1","brief_title":"A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors","source_id_and_acronym":"NCT03289962","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • autogene cevumeran (RG6180)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 12/21/2017","start_date":" 12/21/2017","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-04-26"},{"id":"8f022a9d-6b6c-47b3-b42e-3770069b52cd","acronym":"TROPION-PanTumor02","url":"https://clinicaltrials.gov/study/NCT05460273","created_at":"2022-07-15T16:05:32.169Z","updated_at":"2024-07-02T16:35:09.058Z","phase":"Phase 1/2","brief_title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","source_id_and_acronym":"NCT05460273 - TROPION-PanTumor02","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • HER-2 • ALK • PGR • ROS1 • TACSTD2","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR negative","tags":["EGFR • HER-2 • ALK • PGR • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 07/11/2022","start_date":" 07/11/2022","primary_txt":" Primary completion: 11/07/2023","primary_completion_date":" 11/07/2023","study_txt":" Completion: 05/06/2024","study_completion_date":" 05/06/2024","last_update_posted":"2024-04-17"},{"id":"1903d6da-d5c7-43b4-a343-51787a604398","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070564","created_at":"2021-01-18T00:10:47.683Z","updated_at":"2024-07-02T16:35:09.760Z","phase":"Phase 3","brief_title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT00070564","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3294","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-15"},{"id":"a37af355-2625-4415-ae7c-59d702230ad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776917","created_at":"2021-01-18T13:37:02.048Z","updated_at":"2024-07-02T16:35:10.661Z","phase":"Phase 1","brief_title":"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer","source_id_and_acronym":"NCT02776917","lead_sponsor":"Barbara Parker, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 07/13/2021","primary_completion_date":" 07/13/2021","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-10"},{"id":"2eca1275-9ca8-4c95-8c41-ae4a45c7bd91","acronym":"GeparDouze","url":"https://clinicaltrials.gov/study/NCT03281954","created_at":"2021-01-18T16:12:20.934Z","updated_at":"2024-07-02T16:35:11.046Z","phase":"Phase 3","brief_title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","source_id_and_acronym":"NCT03281954 - GeparDouze","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1550","initiation":"Initiation: 12/19/2017","start_date":" 12/19/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-04-08"},{"id":"3ba19f6b-ef31-414d-988d-c03d4cf8bba9","acronym":"SerMa","url":"https://clinicaltrials.gov/study/NCT05899387","created_at":"2023-06-12T15:08:51.409Z","updated_at":"2024-07-02T16:35:11.057Z","phase":"","brief_title":"Seroma of the Mammary Gland","source_id_and_acronym":"NCT05899387 - SerMa","lead_sponsor":"University Hospital Augsburg","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • ER positive + PGR positive • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER positive + PGR positive • PGR positive • PGR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-04-08"},{"id":"052ff42c-445e-466e-9061-7503375beb53","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349959","created_at":"2021-01-18T05:30:54.553Z","updated_at":"2024-07-02T16:35:11.296Z","phase":"Phase 2","brief_title":"Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT01349959","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jingzhuda (entinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/21/2011","start_date":" 04/21/2011","primary_txt":" Primary completion: 03/27/2014","primary_completion_date":" 03/27/2014","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-04-05"},{"id":"c284c9a8-e24e-458d-9f79-e38507128672","acronym":"","url":"https://clinicaltrials.gov/study/NCT04039230","created_at":"2021-01-18T19:48:59.137Z","updated_at":"2024-07-02T16:35:12.082Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.","source_id_and_acronym":"NCT04039230","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-01"},{"id":"9df7d698-3d6e-4fb5-9f2d-d1c17011273e","acronym":"IRIS","url":"https://clinicaltrials.gov/study/NCT04383275","created_at":"2021-01-18T21:09:55.347Z","updated_at":"2024-07-02T16:35:13.323Z","phase":"Phase 2","brief_title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","source_id_and_acronym":"NCT04383275 - IRIS","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 amplification • ER negative • PGR expression • PGR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 amplification • ER negative • PGR expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 356","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2024-03-22"}]